“Chemobrain” or “chemofog” is a condition that affects cancer survivors who have undergone chemotherapy. Dozens of studies have shown that post-chemotherapy, patients may experience a decline in cognitive performance and memory, and many doctors have long believed chemobrain to be a significant problem for cancer patients. Despite this significant body of evidence, though, some medical professionals continue to dismiss patient claims of cognitive decline as exaggerated or unrelated to their condition.
However, a new study from Stanford University has used brain scans to definitively show that post-chemotherapy, many women show cognitive deficits in the areas of attention, memory, and planning.